Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment

NCT03670069 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT03670069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03670069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2019
Completion date
May 6, 2024
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced leiomyosarcoma, advanced myxoid liposarcoma, advanced soft tissue sarcoma, advanced synovial sarcoma, advanced undifferentiated pleomorphic sarcoma, metastatic chondrosarcoma, metastatic leiomyosarcoma, metastatic myxoid liposarcoma, metastatic round cell liposarcoma, metastatic soft tissue sarcoma, metastatic synovial sarcoma, metastatic undifferentiated pleomorphic sarcoma, refractory leiomyosarcoma, refractory myxoid liposarcoma, refractory round cell liposarcoma, refractory soft tissue sarcoma, refractory synovial sarcoma, refractory undifferentiated pleomorphic sarcoma